TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32247603
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine plus pazopanib
Study: 32247603
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine alone
Study: 32005175
Drug: Continuous intrajejunal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrajejunal Levodopa Infusion (CLI)
Study: 32080823
Drug: Alirocumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 300 mg
Study: 33793556
Drug: Rapid immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid immunoglobulin M (IgM)/immunoglobulin G (IgG) test kit
Study: 32289292
Drug: 4 medications
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 medications
Study: 36064592
Drug: Guselkumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (all dosing regimens)
Study: 32776235
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon catheter (DCB) treatment for ISR
Study: 32776235
Drug: DCB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCB treatment for ISR
Study: 34657160
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) - Healthy Sleep (HS); 4 sessions over 8 weeks
Study: 36235860
Drug: Low-absorbable geraniol
Normalized name: Geraniol
DrugBank: Geraniol (DB14183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-absorbable geraniol food supplement (LAGS) once daily for four weeks
Study: 35333199
Drug: Cannula injection
Normalized name: CANNULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannula injection
Study: 35609024
Drug: Amoxicillin 250mg
Normalized name: AMOXICILLIN 250MG CAP
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 250mg capsule with ranitidine
Study: 35609024
Drug: Amoxicillin 250mg
Normalized name: AMOXICILLIN 250MG CAP
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 250mg capsule without ranitidine
Study: 35217280
Drug: Topical ascorbic
Normalized name: ascorbic acid Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ascorbic acid (30% in 95% DMSO), applied twice daily for 8 weeks
Study: 35217280
Drug: Topical imiquimod,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod, a standard topical treatment
Study: 35217280
Drug: Topical ascorbic
Normalized name: ascorbic acid Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ascorbic acid
Study: 33879842
Drug: Hydromorphone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone + Dronabinol 2.5 mg
Study: 33879842
Drug: Hydromorphone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone + Dronabinol 5 mg
Study: 33879842
Drug: Hydromorphone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone + Dronabinol 10 mg
Study: 33879842
Drug: Dronabinol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (2.5 mg, 5.0 mg, 10 mg)
Study: 32027457
Drug: Fostemsavir 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir 1,200 mg b.i.d.
Study: 32027457
Drug: Fostemsavir 2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir 2,400 mg b.i.d.
Study: 32027457
Drug: TMR concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMR concentrations up to 7,500 ng/mL
Study: 32027457
Drug: Fostemsavir 600
Normalized name: fostemsavir 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostemsavir 600 mg b.i.d. (in phase III BRIGHTE study)
Study: 35012798
Drug: Neoadjuvant dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Study: 35782290
Drug: Online laughter
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online laughter therapy (10 sessions, 2 days a week for 5 weeks)
Study: 32567237
Drug: Eye patching
Normalized name: PATCH,EYE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye patching with a single dose of local steroid and antibiotic for 24 hours
Study: 32567237
Drug: Plastic shield
Normalized name: Peroxy Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plastic shield with local steroid and antibiotic drops
Study: 32621741
Drug: 1 mOPV2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mOPV2 dose
Study: 32621741
Drug: 2 mOPV2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mOPV2 doses
Study: 35876018
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase treatment (IVT) followed by endovascular treatment (EVT)
Study: 35232755
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) alone
Study: 34167594
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conjugated estrogens 0.45 mg and bazedoxifene acetate 20 mg (Duavive)
Study: 35262461
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality technology for intravenous catheterization training
Study: 35262461
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection arm model (control)
Study: 32899073
Drug: True acupoints
Approvals — FDA: no, EMA: no, PMDA: no
Description: True acupoints treatment group (TATG)
Study: 32899073
Drug: Sham acupoints
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupoints treatment group (SATG)
Study: 34320413
Drug: ChAdOx1-S (AZD1222)
Normalized name: TPG-S
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ChAdOx1-S (AZD1222) vaccine
Study: 35727711
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 400 mg
Study: 35727711
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1600 mg
Study: 32097092
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 75 mg/m2 every 3 weeks × 4 doses
Study: 32097092
Drug: Doxorubicin-Cyclophosphamide (AC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-Cyclophosphamide (AC) doxorubicin 60 mg/m2; cyclophosphamide 600 mg/m2 every 2-3 weeks × 4 doses
Study: 34907536
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent apheresis fresh-frozen plasma (CC-AFFP)
Study: 35332736
Drug: Oxytocin injection
Normalized name: Oxytocin Injection
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin injection plus ergometrine injection
Study: 35332736
Drug: Oxytocin injection
Normalized name: Oxytocin Injection
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin injection
Study: 35698580
Drug: Masitinib (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib (6 mg/kg/d)
Study: 35801005
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg 2 hours before surgery, 40 mg/day after surgery, and 20 mg/day 1 week later
Study: 35801005
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg every night after admission (Control)
Study: 34871052
Drug: Best practice
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practice advice with corticosteroid injection
Study: 34871052
Drug: Best practice
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practice advice without corticosteroid injection
Study: 32330373
Drug: Verum test
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum test dietary supplement (TDS) containing l-carnitine/acetyl-l-carnitine, l-arginine, glutathione, co-enzyme Q10, zinc, vitamin B9, vitamin B12, selenium, taken 1 time daily for 6 months
Study: 32330373
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken 1 time daily for 6 months
Study: 32330373
Drug: Verum test
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum test dietary supplement (TDS)
Study: 36001306
Drug: Psilocybin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (25 mg/70 kg for first session; 25-40 mg/70 kg for second session)
Study: 36001306
Drug: Diphenhydramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg for first session; 50-100 mg for second session)
Study: 32243943
Drug: Hydrocortisone, vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone, vitamin C, and thiamine combination treatment
Study: 32481760
Drug: WHS 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHS 300 mg
Study: 32481760
Drug: WHS 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHS 600 mg
Study: 32939860
Drug: Brodalumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab (210 mg subcutaneous injections)
Study: 32216032
Drug: 50 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU/kg Eprex (low-dose)
Study: 32216032
Drug: 20 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU/kg Eprex (micro-dose)
Study: 32797324
Drug: L-POCs group
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-POCs group (C-D = I-II)
Study: 34430440
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy alone (Control group)
Study: 32820475
Drug: Inotropic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotropic agents (e.g., dobutamine)
Study: 33795322
Drug: ICS/LABA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA therapy for 12 weeks
Study: 33065820
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Social Rhythm Group Therapy (CBSRT)
Study: 35790329
Drug: Social Participation-focused
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Participation-focused Virtual Reality (SP-VR) intervention, 6-week program with two sessions weekly.
Study: 35790329
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (conventional physical therapy services)
Study: 34791679
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg every 2 weeks for 16 weeks) plus timothy grass (TG) SCIT
Study: 33439945
Drug: 50 IU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU/mL heparin solution
Study: 33439945
Drug: 0.9% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% isotonic saline solution
Study: 32887653
Drug: Daily aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily aspirin therapy (100 or 300 mg)
Study: 39236736
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg infliximab
Study: 34090870
Drug: 20% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Intralipid infusion
Study: 34703265
Drug: Setipiprant 1000
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant 1000 mg BID
Study: 35570397
Drug: topical β-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical β-glucan
Study: 35570397
Drug: 1565-nm NAFL
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1565-nm NAFL combined with topical β-glucan (B + NAFL)
Study: 35570397
Drug: 1565-nm NAFL
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1565-nm NAFL combined with topical vehicle (NAFL)
Study: 35570397
Drug: topical vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical vehicle (Veh)
Study: 32266494
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (CON, n=13)
Study: 32538776
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus (2 strains, 5 x 10^9 cfu/capsule)
Study: 35455507
Drug: Massage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage with oil (isio4 10 mL/kg/day)
Study: 35758895
Drug: Adenosine A2A
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine A2A receptor antagonist
Study: 34606578
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (2 units, total volume of 550 mL)
Study: 34507573
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (n=382)
Study: 34507573
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Roux-en-Y gastric bypass, n=388; sleeve gastrectomy, n=201)
Study: 33295083
Drug: Inhaled PDE4i
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled PDE4i CHF6001 (tanimilast)
Study: 36447137
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.375% ropivacaine
Study: 36447137
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.375% ropivacaine
Study: 36447137
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 0.375% ropivacaine
Study: 32092310
Drug: IW-3718 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-3718 1500 mg
Study: 32092310
Drug: IW-3718 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-3718 500 mg
Study: 32092310
Drug: IW-3718 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-3718 1000 mg
Study: 36300974
Drug: DHA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA group (60 mg of DHA per kilogram of body weight per day)
Study: 33346335
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg/d)
Study: 33346335
Drug: Efavirenz-based therapy
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz-based therapy
Study: 32333636
Drug: Financial toxicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial toxicity sources including travel to and from the hospital and reduced working hours during treatment
Study: 35936068
Drug: Ketamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (10 μg/kg/min)
Study: 33333508
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy with VR and MI techniques, 60-min sessions, every alternate day for 12 weeks
Study: 33333508
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy, 40-min sessions, 20 min of walking and cycling, every alternate day for 12 weeks
Study: 33228625
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) package offered to half of the smokers interested in receiving it.
Study: 33228625
Drug: No nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No nicotine patches offered to the other half of smokers.
Study: 35389359
Drug: Pharmacist-led web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led web-based medication adherence tool with patient-centered communication
Study: 35763327
Drug: Bionic Pancreas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionic Pancreas (BP) with insulin aspart or insulin lispro, N=112
Study: 32271710
Drug: Topical silicone-based
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone-based scar cream containing selective synthetic recombinant human growth factors, hyaluronic acid, and vitamin C applied twice a day for 1 month.
Study: 32271710
Drug: Topical silicone-based
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone-based scar cream (treated group)
Study: 33706428
Drug: Stepwise pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise pain management (oral acetaminophen 10-15 mg/kg every 4-6 hours for moderate pain, morphine 0.1-0.2 mg/kg every 4 hours for severe pain)
Study: 34144603
Drug: MTX-PGs levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-PGs levels >134 nmol/l
Study: 34556722
Drug: Normobaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric oxygen treatment (35% fraction of inspired oxygen)
Study: 35940872
Drug: Dextrose gel
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose gel (40% dextrose)
Study: 34052785
Drug: mHealth technology-centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth technology-centered intervention using a Vaica electronic pill tray and blue-toothed UA-767Plus BT blood pressure device with a dedicated app for data relay.
Study: 36478707
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil (2 μg) with 10 mg intrathecal bupivacaine
Study: 36478707
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl (10 μg) with 10 mg intrathecal bupivacaine
Study: 36478707
Drug: Intravenous cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocktail of 1 g acetaminophen, 5 mg morphine, and 100 μg fentanyl with 10 mg intrathecal bupivacaine
Study: 33177476
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (LDMTX) 10 mg
Study: 33047449
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise associated with abdominal laser therapy (LLLT) for 50 minutes at 45%-55% of reserve heart rate
Study: 33086652
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels <30 nmol/L in the first trimester
Study: 33086652
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels <20 nmol/L in the first trimester
Study: 33086652
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels <30 nmol/L in the third trimester
Study: 32666123
Drug: Lusutrombopag 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag 0.75 mg for 6 days (first dose: 1.5 mg)
Study: 32666123
Drug: Cyclosporine 400-600
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 400-600 mg
Study: 35933379
Drug: Lacrystim® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacrystim® treatment (3 IPL sessions at D0, D15, and D45 with 4 shots per side at a fluence of 8 mJ/cm2)
Study: 35933379
Drug: Lacrystim® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacrystim® treatment
Study: 35196668
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (chemotherapy and radiation therapy)
Study: 33250396
Drug: Therapy program
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy program with strengthening (Group 1, n = 38)
Study: 33250396
Drug: Therapy program
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy program without strengthening (Group 2, n = 21)
Study: 33524052
Drug: Brucella antibodies
Normalized name: Brucella melitensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brucella antibodies by IgG ELISA
Study: 33524052
Drug: Brucella antibodies
Normalized name: Brucella melitensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brucella antibodies by IgM ELISA
Study: 33524052
Drug: Brucella antibodies
Normalized name: Brucella melitensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brucella antibodies by RBT
Study: 33208303
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) treatment
Study: 35999942
Drug: Repeat pulmonary
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat pulmonary rehabilitation program (twice in 12 months)
Study: 34654584
Drug: High VRSA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High VRSA dosage (H-VRSA)
Study: 34654584
Drug: Low VRSA
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low VRSA dosage (L-VRSA)
Study: 34705756
Drug: IV TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV TXA followed by oral TXA for 2 days (group 2D, n = 46)
Study: 34705756
Drug: IV TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV TXA followed by oral TXA for 5 days (group 5D, n = 47)
Study: 33122892
Drug: Evogliptin 5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin 5 mg once daily for 7 days (EVO)
Study: 33122892
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of evogliptin 5 mg and pioglitazone 30 mg once daily for 7 days (EVO+PIO)
Study: 33122892
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily for 7 days (PIO)